We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
CTMX | CytomX Therapeutics Inc | 4.1186 | 2.49 | 152.67% | 154,602,551 |
SYT | SYLA Technologies Company Ltd | 3.44 | 1.98 | 135.62% | 9,674,469 |
PBM | Psyence Biomedical Ltd | 1.33 | 0.4306 | 47.88% | 3,456,400 |
IMCC | IM Cannabis Corporation | 1.14 | 0.28 | 32.56% | 37,652,782 |
SRDX | SurModics Inc | 33.72 | 8.03 | 31.26% | 98,197 |
TMDX | TransMedics Group Inc | 119.885 | 25.76 | 27.36% | 3,337,123 |
PALI | Palisade Bio Inc | 7.5899 | 1.56 | 25.87% | 11,683,796 |
BCLI | Brainstorm Cell Therapeutics Inc | 0.468899 | 0.0914 | 24.21% | 1,284,737 |
RCKY | Rocky Brands Inc | 32.00 | 6.23 | 24.18% | 120,159 |
AKAN | Akanda Corporation | 0.1147 | 0.0217 | 23.33% | 167,769,333 |
POWL | Powell Industries Inc | 175.00 | 32.00 | 22.38% | 737,067 |
TORONTO and GLIL YAM, Israel, May 1, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2024 ended March 31, 2024, on Wednesday, May 8, 2024, before the market opens.
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024.
ANDOVER, Mass., April 30, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024.
- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors - TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, "Poseida") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
NWBO | NorthWest Biotherapeutics Inc | 288 | |
BLEG | Branded Legacy Inc | 152 | |
SPZI | SPOOZ Inc | 102 | |
4 | RDGL | Vivos Inc | 56 |
5 | ELTP | Elite Pharmaceuticals Inc | 64 |
6 | VPLM | Voip Pal Com Inc | 39 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 56,801.66 | -3,798.62 | -6.27% | 1.12T | 7,802,333,051 |
ETH | Ethereum | 2,875.23 | -135.58 | -4.50% | 346.85B | 3,151,732,496 |
USDT | Tether USD | 0.99878 | -0.00037 | -0.04% | 97.73B | 377,146,218 |
BNB | Binance Coin | 544.38 | -33.20 | -5.75% | 86.08B | 468,630,698 |
SOL | Solana | 124.30 | -2.43 | -1.92% | 54.79B | 1,347,135,527 |
STETH | stETH | 2,862.89 | -145.82 | -4.85% | 28.2B | 11,134,733 |
USDC | USD Coin | 0.9999 | 0.00 | 0.00% | 28.07B | 1,000,370,501 |
XRP | Ripple | 0.5015 | 0.0015 | 0.30% | 27.28B | 361,904,755 |
DOGE | Dogecoin | 0.12273 | -0.0104 | -7.81% | 17.61B | 561,847,644 |
TONCOIN | Wrapped TON Coin | 4.61 | -0.551849 | -10.68% | 16.06B | 125,221,013 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions